Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aerie's M&A Potential Rises As Roclatan Passes Second Phase III Glaucoma Test

Executive Summary

Positive Phase III data for Aerie's second glaucoma drug candidate Roclatan – which will support a US FDA submission in the first half of 2018 – have boosted the California company's M&A allure.

Advertisement

Related Content

Aerie's Netarsudil Headed For Broad Indication With Only Subpopulation Efficacy
Aerie's Netarsudil's Safety Questions May Determine Fate At Advisory Committee
Inotek Considers Its Options After Another Glaucoma Failure
Finance Watch: Bicycle Spins Toward Clinic With $52m Round; Stock Spikes Spur Offerings
Keeping Track: Xermelo, Odactra, Noctiva Approved; Second Submissions For Avelumab And Deutetrabenazine
Inotek Plummets On Glaucoma Phase III Failure
Aerie ROCKETS On Glaucoma Data

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC098820

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel